ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
35 announcements
Vimta Labs incorporated wholly owned US subsidiary Vimta Labs LLC, investing about INR 0.08 Crore (USD 8,500). The contract research unit supports the parent's testing business.
Stable Q2 performance masked by R&D lulls and logistics headwinds.
Vimta Labs reported Q2 FY27 income of ₹1,149 Mn, up 9.9% YoY, and PAT of ₹206 Mn at 17.9% margin. EBITDA margins held steady at 35.5%.
Q2 FY27: total income Rs1,149Mn (+9.9% YoY), EBITDA Rs408Mn (35.5% margin), PAT Rs206Mn (17.9% margin, +3.5% YoY). H1 FY27 PAT Rs417Mn (+7.3%).
Vimta Labs Ltd reported revenue from operations of ₹112 Cr (+10.0% YoY) and net profit of ₹20.6 Cr (+3.5% YoY) for Q2 FY27.
Vimta Labs will hold a board meeting on 30 October 2026 to consider half-year results. Trading window stays closed from 01 October.
Vimta Labs Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.
Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
Vimta Labs Ltd filed its quarterly shareholding pattern disclosure for the period ending June 30, 2026, pursuant to SEBI Regulation 31(1)(b).
Vimta Labs announced Q1 FY27 results with total income of ₹112.90 Crore. The company reported a PAT of ₹21.00 Crore for the quarter.
Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.
Vimta Labs Ltd reported revenue from operations of ₹109.1 Cr (+11.8% YoY) and net profit of ₹21 Cr (+11.1% YoY) for Q1 FY27.
Vimta Labs scheduled a board meeting on July 20, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Vimta Labs paid ₹2 per share dividend for FY2025-26, approved at AGM. Payment completed on 04 July 2026 to eligible shareholders.
Vimta Labs allotted 17,549 equity shares following ESOP exercises. This increases the total paid-up share capital to 44,686,904 shares.
Vimta Labs allotted 17,549 equity shares under its ESOP 2021 plan. The shares were issued at a face value of ₹2 each.
Vimta Labs re-appointed Sivalinga Prasad Vasireddi as Executive Director for five years. The change is effective from July 01, 2026.
Vimta Labs held its 36th AGM on June 25, 2026. The meeting covered financial statements, dividend declarations, and director appointments.
Vimta Labs Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The disclosure outlines the company's ESG performance and sustainability initiatives for the year.
Vimta Labs Limited submitted its Annual Report and BRSR for FY 2025-26. The 36th Annual General Meeting is scheduled for June 25, 2026.
Vimta Labs Limited has scheduled its 36th Annual General Meeting for June 25, 2026. The agenda includes dividend declaration and reappointment of the Executive Chairman.
Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.
Vimta Labs Limited recommended a dividend of ₹2 per equity share for FY 2025-26. The record date is June 18, 2026, with payment scheduled on or before July 8, 2026, subject to shareholder approval.
Vimta Labs Limited has recommended the re-appointment of Dr. S. P. Vasireddi as Executive Chairman for a five-year term effective from July 1, 2026, to June 30, 2031. The appointment is subject to shareholder approval at the upcoming Annual General Meeting. Dr. Vasireddi is the company's founder with over four decades of experience.
Vimta Labs Limited reported a 19.5% YoY revenue growth for FY26, reaching ₹416.3 Crore. The company achieved its highest-ever quarterly revenue of ₹112.0 Crore in Q4 FY26. Full-year EBITDA margins stood at 35.8% with a PAT margin of 18.6%, driven by strong performance in Pharma and Food divisions.
Vimta Labs reported Q4 FY26 revenue of ₹1,120 Mn and PAT of ₹211 Mn with strong margins across TIC segments.